Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Prev Med Hyg ; 53(2): 104-8, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23240170

RESUMEN

INTRODUCTION: Sepsis is a major cause of significant morbidity and mortality in neutropenic patients. Blood culture remains the gold standard in the microbiological diagnosis of bacterial or fungal bloodstream infections, but it has clear limits of rapidity and sensitivity. The objective of the study was to compare the real-time polymerase chain reaction (RT-PCR) with automated blood cultures (BC) method in detection in whole blood of pathogens in febrile neutropenic patients with hematological malignancies. METHODS: A total of 166 consecutive febrile neutropenic patients were enrolled. Blood samples for cultures and SeptiFast testing were obtained at the onset of fever, before the implementation of empirical antibiotic therapy. RESULTS: Forty (24.1%) samples out of the 166 blood samples tested, were positive by at least one method. Twenty-three (13.9%) samples were positive by blood culture and 38 (22.9%) by multiplex real-time PCR. The analysis of concordance evidenced a low correlation between the two methods (n = 21; 52.5%), mainly due to samples found negative by culture but positive with the Septi-Fast assay. Sensitivity, specificity, and positive and negative predictive values of RT-PCR were 91.3%, 88.1%, 55.3%, and 98.4%, respectively, compared with BC. DISCUSSION: Multiplex real-time PCR assay improved detection of the most bacteria associated with febrile neutropenia episodes. Further studies are needed to assess the real advantages and clinical benefits that molecular biology tests can add in diagnosis of sepsis.


Asunto(s)
Recolección de Muestras de Sangre/métodos , Neoplasias Hematológicas/complicaciones , Técnicas de Diagnóstico Molecular/métodos , Neutropenia/complicaciones , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sepsis/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Sensibilidad y Especificidad , Sepsis/microbiología
2.
Int J Cardiol ; 310: 138-144, 2020 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-32139240

RESUMEN

BACKGROUND: Normal standards for peak oxygen consumption (VO2peak) are controversial because they tend to be population and protocol specific. This study was undertaken to examine the association between percentage of age-predicted VO2peak and all-cause hospital readmission in cardiac outpatients who were referred to an exercise-based secondary prevention program. METHODS: Hospital readmission was assessed in 1283 male patients with coronary heart disease (CHD) three years after enrolment, and related to the age-predicted VO2peak derived from the Fitness Registry and the Importance of Exercise: A National Data Base equation (FRIEND%PRED). VO2peak was estimated using a moderate perceptually regulated 1-km treadmill-walking test. Readmission was also assessed during the fourth-to-sixth years as function of improvement in FRIEND%PRED in 845 patients who were re-evaluated 3 years after baseline. RESULTS: During the 3-years after baseline, readmission rate was lower across increasing tertiles of FRIEND%PRED. Compared to the lowest tertile, the adjusted hazard ratios (HRs) for the second and third tertile were 0.98 (95% CI 0.76-1.27, p = 0.90) and 0.71 (0.53-0.95, p = 0.002). The rate of readmission from the fourth-to-sixth years after baseline was lower across tertiles of improved FRIEND%PRED, with adjusted HRs 0.78 (0.60-1.03, p = 0.08) and 0.58 (0.42-0.75, p < 0.0001) for the intermediate and high tertiles vs the lowest tertile. After adjustment for confounders, every 1 unit % increase in FRIEND%PRED was associated with a 3% reduction in risk of readmission (HR 0.97, 0.95-0.98, p < 0.0001). CONCLUSIONS: Age-predicted VO2peak estimated by a moderate treadmill-walk predicts hospital readmission in outpatients with CHD undergoing secondary prevention.


Asunto(s)
Enfermedad Coronaria , Consumo de Oxígeno , Enfermedad Coronaria/diagnóstico , Enfermedad Coronaria/epidemiología , Prueba de Esfuerzo , Humanos , Masculino , Sistema de Registros , Caminata
3.
Am J Hypertens ; 18(9 Pt 2): 142S-154S, 2005 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16125051

RESUMEN

Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Its efficacy, safety, and tolerability are well established in the treatment of hypertension and heart failure. Moreover, large morbidity-mortality trials, such as the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) and Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS), have shown that antihypertensive treatment with perindopril reduces and prevents cardiovascular disease in a large range of patients with vascular diseases, whether or not they are hypertensive. Thus, the outcomes of these and other trials support the concept of cardiovascular protective properties of angiotensin-converting enzyme inhibition with perindopril in addition to the obvious blood-pressure-lowering effect. Considering its properties and the clinical evidence on efficacy and tolerability that has been gathered, perindopril fulfils the criteria of the latest guidelines for hypertension and cardiovascular disease management and should therefore be considered as a first-line antihypertensive agent, forming a consistent part of the comprehensive strategy against hypertension and related cardiovascular complications.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Perindopril/uso terapéutico , Sistema Renina-Angiotensina/efectos de los fármacos , Presión Sanguínea/efectos de los fármacos , Trastornos Cerebrovasculares/tratamiento farmacológico , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Insuficiencia Cardíaca/tratamiento farmacológico , Humanos , Hipertensión/tratamiento farmacológico
4.
Int J Cardiol ; 114(3): e85-8, 2007 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-16935364

RESUMEN

Only a few reports are available on the Tako-Tsubo syndrome in Caucasian patients. The aetiology remains unknown but several pathophysiological mechanisms have been proposed so far. We believe that this condition is not so rare in Caucasian patients because many diagnoses may be missed or misinterpreted. Tissue Doppler evaluation identifies myocardial reversible dysfunction, putatively stunning, at the onset of cardiomyopathy. This can help in diagnosis, prognosis and in choosing the best time for coronary angiography.


Asunto(s)
Ecocardiografía Doppler , Disfunción Ventricular Izquierda/diagnóstico por imagen , Angiografía Coronaria , Vasos Coronarios/fisiopatología , Electrocardiografía , Femenino , Humanos , Persona de Mediana Edad , Disfunción Ventricular Izquierda/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA